Celldex Therapeutics
CLDX
$42.56
Share price
4.16%
Change (1 day)
35.15%
Change (1 year)
Categories
P/S ratio for Celldex Therapeutics (CLDX)
P/S ratio as of May 2024 (TTM): 391
According to Celldex Therapeutics's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 391.269. At the end of 2023 the company had a P/S ratio of 315.
P/S ratio history for Celldex Therapeutics from 2001 to 2023
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2023 | 315 | -64.62% |
| 2022 | 891 | 129.46% |
| 2021 | 388 | 314.91% |
| 2020 | 93.5 | 783.15% |
| 2019 | 10.6 | 184.57% |
| 2018 | 3.72 | -87.72% |
| 2017 | 30.3 | -42.63% |
| 2016 | 52.8 | -81.29% |
| 2015 | 282 | -38.08% |
| 2014 | 456 | -13.25% |
| 2013 | 526 | 1263.33% |
| 2012 | 38.6 | 211.18% |
| 2011 | 12.4 | 338.95% |
| 2010 | 2.82 | -71.05% |
| 2009 | 9.75 | -41.89% |
| 2008 | 16.8 | 23.99% |
| 2007 | 13.5 | -33.39% |
| 2006 | 20.3 | -55.02% |
| 2005 | 45.1 | 107.81% |
| 2004 | 21.7 | -43.23% |
| 2003 | 38.3 | 274.72% |
| 2002 | 10.2 | -85.9% |
| 2001 | 72.4 |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | 2.68 | -99.31% | 🇺🇸 USA |
 Amgen AMGN | 5.30 | -98.65% | 🇺🇸 USA |
 GlaxoSmithKline GSK | 2.34 | -99.40% | 🇬🇧 UK |
 Titan Pharmaceuticals
TTNP | > 1000 | 1,465.51% | 🇺🇸 USA |
 Seagen
SGEN | 18.8 | -95.21% | 🇺🇸 USA |
 Agenus
AGEN | 1.68 | -99.57% | 🇺🇸 USA |
 Emergent BioSolutions
EBS | 0.1689 | -99.96% | 🇺🇸 USA |